Michael D. Huband
About
Michael D. Huband is a scholar working on Molecular Medicine, Pharmacology and Infectious Diseases.
According to data from OpenAlex, Michael D. Huband has authored 113 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Molecular Medicine, 55 papers in Pharmacology and 39 papers in Infectious Diseases. Recurrent topics in Michael D. Huband's work include Antibiotic Resistance in Bacteria (68 papers), Antibiotics Pharmacokinetics and Efficacy (47 papers) and Antibiotic Use and Resistance (35 papers). Michael D. Huband is often cited by papers focused on Antibiotic Resistance in Bacteria (68 papers), Antibiotics Pharmacokinetics and Efficacy (47 papers) and Antibiotic Use and Resistance (35 papers). Michael D. Huband collaborates with scholars based in United States, United Kingdom and Japan. Michael D. Huband's co-authors include Robert K. Flamm, Mariana Castanheira, Michael A. Pfaller, Hélio S. Sader, Rodrigo E. Mendes, Dee Shortridge, Paul R. Rhomberg, Ronald N. Jones, Michael Cohen and Jennifer M Streit and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Journal of Medicinal Chemistry.
In The Last Decade
Michael D. Huband
109 papers receiving 2.7k citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael D. Huband United States | 30 | 1.5k | 986 | 719 | 708 | 683 | 113 | 2.8k | ||
| Alfred S. Gin Canada | 22 | 1.8k 1.2× | 1.6k 1.6× | 1.1k 1.5× | 846 1.2× | 610 0.9× | 37 | 3.4k | ||
| Alita A. Miller United States | 32 | 1.5k 1.1× | 815 0.8× | 530 0.7× | 554 0.8× | 1.0k 1.5× | 72 | 3.0k | ||
| Yigong Ge United States | 28 | 958 0.7× | 1.0k 1.0× | 634 0.9× | 759 1.1× | 721 1.1× | 36 | 2.6k | ||
| Katherine Young United States | 35 | 2.2k 1.5× | 1.7k 1.7× | 704 1.0× | 292 0.4× | 845 1.2× | 117 | 3.7k | ||
| Mary Motyl United States | 38 | 2.0k 1.4× | 1.4k 1.5× | 1.5k 2.1× | 1.3k 1.8× | 530 0.8× | 132 | 4.1k | ||
| Thomas D. Gootz United States | 36 | 1.5k 1.0× | 1.2k 1.2× | 661 0.9× | 490 0.7× | 1.3k 1.9× | 60 | 3.4k | ||
| Jean‐Denis Docquier Italy | 34 | 3.1k 2.1× | 1.0k 1.0× | 686 1.0× | 614 0.9× | 1.4k 2.0× | 115 | 3.9k | ||
| Magdalena A. Taracila United States | 33 | 2.8k 2.0× | 1.5k 1.5× | 848 1.2× | 383 0.5× | 808 1.2× | 75 | 3.5k | ||
| Elizabeth B. Hirsch United States | 21 | 1.2k 0.8× | 658 0.7× | 578 0.8× | 238 0.3× | 364 0.5× | 68 | 2.0k | ||
| Philip Lister United States | 24 | 1.7k 1.2× | 853 0.9× | 591 0.8× | 218 0.3× | 985 1.4× | 50 | 2.6k |
Countries citing papers authored by Michael D. Huband
Since
Specialization
Citations
This map shows the geographic impact of Michael D. Huband's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Huband with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Huband more than expected).
Fields of papers citing papers by Michael D. Huband
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael D. Huband. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Huband. The network helps show where Michael D. Huband may publish in the future.
Co-authorship network of co-authors of Michael D. Huband
This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Huband. A scholar is included among the top collaborators of Michael D. Huband based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Huband. Michael D. Huband is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Aronin, Steven I., et al.. (2025). In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023. Journal of Global Antimicrobial Resistance. 44. 152–159.
2.
Huband, Michael D., et al.. (2025). Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023). Diagnostic Microbiology and Infectious Disease. 111(3). 116711–116711.
3.
Winkler, Marisa, et al.. (2024). Use of voriconazole to predict susceptibility and resistance to isavuconazole for Aspergillus fumigatus using CLSI methods and interpretive criteria. Journal of Clinical Microbiology. 63(2). e0120724–e0120724.
4.
McLeod, Sarah M., Nicole Carter, Michael D. Huband, et al.. (2023). Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. Journal of Clinical Microbiology. 62(1). e0122823–e0122823.
5.
Huband, Michael D., Rodrigo E. Mendes, Gina Morgan, Holly K. Huynh, & Mariana Castanheira. (2023). 2517. Activity of Sulbactam-durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates. Open Forum Infectious Diseases. 10(Supplement_2).
6.
Carvalhaes, Cecília G, Paul R. Rhomberg, Michael D. Huband, Michael A. Pfaller, & Mariana Castanheira. (2023). Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific. Journal of Fungi. 9(2). 241–241.
7.
Maher, Joshua, et al.. (2023). In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program. Journal of Antimicrobial Chemotherapy. 78(6). 1406–1414.
8.
Huang, David B., et al.. (2021). In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018. Journal of Global Antimicrobial Resistance. 25. 14–17.
9.
Mendes, Rodrigo E., Michael D. Huband, Jennifer M Streit, Mariana Castanheira, & Robert K. Flamm. (2020). Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. Diagnostic Microbiology and Infectious Disease. 97(3). 115054–115054.
10.
Sader, Hélio S., Jennifer M Streit, Cecília G Carvalhaes, Michael D. Huband, & Michael A. Pfaller. (2018). Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America. Journal of Global Antimicrobial Resistance. 17. 103–108.
11.
Huband, Michael D., Mariana Castanheira, David J. Farrell, et al.. (2016). In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). International Journal of Antimicrobial Agents. 47(6). 495–499.
12.
Huband, Michael D.. (2011). Prosthetic Rehabilitation. Dermatologic Clinics. 29(2). 325–330.
13.
Muñoz-Price, L. Silvia, Carolina De La Cuesta, Stephen Adams, et al.. (2010). Successful Eradication of a Monoclonal Strain ofKlebsiella pneumoniaeduring aK. pneumoniaeCarbapenemase-ProducingK. pneumoniaeOutbreak in a Surgical Intensive Care Unit in Miami, Florida. Infection Control and Hospital Epidemiology. 31(10). 1074–1077.
14.
Starr, Jeremy T., Richard J. Sciotti, Debra Hanna, et al.. (2009). 5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV. Bioorganic & Medicinal Chemistry Letters. 19(18). 5302–5306.
15.
Kim, Jiyoung, et al.. (2008). Synthesis and structure–activity studies of novel homomorpholine oxazolidinone antibacterial agents. Bioorganic & Medicinal Chemistry Letters. 19(2). 550–553.
16.
Tran, Tuan P., Edmund L. Ellsworth, Brian M. Watson, et al.. (2008). Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorganic & Medicinal Chemistry Letters. 18(18). 5087–5090.
17.
Huband, Michael D.. (2008). In Vitro Antibacterial Activity of Sulopenem: A New Oral Penem Antimicrobial Versus Recent Bacterial Clinical Isolates. 46th Annual Meeting.
18.
Boyer, F, J. V. N. Vara Prasad, Allison L. Choy, et al.. (2007). Synthesis and SAR of novel conformationally-restricted oxazolidinones possessing Gram-positive and fastidious Gram-negative antibacterial activity. Part 1: Substituted pyrazoles. Bioorganic & Medicinal Chemistry Letters. 17(16). 4694–4698.
19.
Prasad, J. V. N. Vara, F Boyer, Susan E. Hagen, et al.. (2006). Synthesis and structure–activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents. Bioorganic & Medicinal Chemistry Letters. 16(20). 5392–5397.
20.
Sanchez, Joseph P., Rocco D. Gogliotti, John M. Domagala, et al.. (1995). The Synthesis, Structure-Activity, and Structure-Side Effect Relationships of a Series of 8-Alkoxy- and 5-Amino-8-alkoxyquinolone Antibacterial Agents. Journal of Medicinal Chemistry. 38(22). 4478–4487.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alfred S. Gin Breakdown of academic impact, for papers by Alita A. Miller Breakdown of academic impact, for papers by Yigong Ge Breakdown of academic impact, for papers by Katherine Young Breakdown of academic impact, for papers by Mary Motyl Breakdown of academic impact, for papers by Thomas D. Gootz Breakdown of academic impact, for papers by Jean‐Denis Docquier Breakdown of academic impact, for papers by Magdalena A. Taracila Breakdown of academic impact, for papers by Elizabeth B. Hirsch Breakdown of academic impact, for papers by Philip Lister